XML 22 R13.htm IDEA: XBRL DOCUMENT v3.23.3

Asset Impairment, Restructuring, and Other Special Charges	9 Months Ended
	Sep. 30, 2023
Restructuring and Related Activities [Abstract]
Asset Impairment, Restructuring, and Other Special Charges	Asset Impairment, Restructuring, and Other Special Charges There were no asset impairment, restructuring, and other special charges recognized during the three and nine months ended September 30, 2023. We recognized $206.5 million of asset impairment, restructuring, and other special charges during the three and nine months ended September 30, 2022, primarily related to an intangible asset impairment for GBA1 Gene Therapy, acquired in the acquisition of Prevail Therapeutics Inc., as a result of changes in key assumptions used in the valuation due to delays in estimated launch timing.

X

- References

No definition available.

+ Details

Name:	us-gaap_RestructuringAndRelatedActivitiesAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The entire disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.

+ References

No definition available.

+ Details

Name:	us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration